Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNF inhibitor dose reduction strategy study in psoriatic arthritis and axial spondyloarthritis
NL-OMON49692Completed
- Sponsor
- Sint Maartenskliniek
- Start
- Jan 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of adalimumab, certolizumab pegol, etanercept, golimumab and infliximab in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) (2 arms), sponsored by Sint Maartenskliniek. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NL-OMON49692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49692.